Lexon told a judge today that the UK competition authority's enforcers wrongly analyzed the content and context of discussions between drug companies over the market supply of an antidepressant medication.
The drugmaker, which is appealing a Competition and Markets Authority decision from earlier this year, said the communication, spanning text messages,